In February, a group of researchers initiated a major new survey of patient knowledge about active surveillance as an initial management option for men with lower risk forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: patient, active, surveillance, survey, knowledge | Leave a comment »
Xofigo (radium Ra 223 dichloride) is a systemic radiopharmaceutical. Radium is chemically similar to calcium and is taken up by bones in places where bone is actively growing, as in prostate cancer bone metastases. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: combination, radium-223, therapy, Xofigo | Leave a comment »
As we have mentioned previously, data on the use of a variety of methods of urine testing in assessment of risk for clinically significant prostate cancer (and therefore the need for a follow-up biopsy) continues to evolve. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: MyProstateScore, risk, test, urine | Leave a comment »
We saw recently (see this link) that of chemotherapeutic and hormonal medicines for treatment of metastatic castration-resistant prostate cancer (mCRPC), Jevtana (cabazitaxel) is the preferred third-line treatment after Taxotere (docetaxel) and Zytiga (abiraterone acetate) or Xtandi (enzalutamide). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, Jevtana, Lu-177-PSMA-617, mCRPC | 3 Comments »
The abstract of a presentation to be given by Egan et al. — from the National Institutes of Health (NIH) at Bethesda, MD — at the upcoming, virtual Genitourinary Cancers Symposium has indicated that active surveillance (AS) seems to be a very reasonable option for first-line management for compliant patients initially diagnosed with Grade Group 2 prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: 2, active, grade group, progression, surveillance | 9 Comments »
The “best” way to identify clinically significant, localized prostate cancer continues to evolve. But there is still no consensus about what that “best” way might be to do this, let alone any consensus about the detection of “clinically insignificant”, localized prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, MRi-guided, risk, systematic | Leave a comment »
Early in 2020, in the initial stages of the COVID-19 pandemic, there was a suggestion (based on data from a small Italian study) that men who were using androgen deprivation therapy (ADT) to manage their prostate cancer might be at lower than average risk for becoming infected with this virus. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, COVID-19, risk | 3 Comments »
As we await the results of the VISION trial of Lu-177-PSMA-617, research continues into improving radiopharmaceuticals. … READ MORE …
Filed under: Drugs in development | Tagged: Ac-225, actinium-225, PSMA, radiopharmaceuticals, safety, side effects, targeted, xerostomia | 3 Comments »
Two technologies have come together to allow for a new kind of radiation treatment known as simultaneous integrated boost (SIB), or, more informally, “dose painting.” … READ MORE …
Filed under: Diagnosis, Management, Treatment | Tagged: boost, dose painting, integrated, radiation, SIB, simultaneous | 5 Comments »
As we have seen, stereotactic body radiation therapy (SBRT) is a preferred therapy for low- and intermediate-risk patients (see this link). It is effective, safe, convenient, and relatively inexpensive. However, its use for high-risk patients remains controversial. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", intermediate risk, outcomes, radiation | 5 Comments »
It is becoming very clear that over the next 5 to 10 years we will develop a whole new spectrum of urine-based tests for the assessment of risk for prostate cancer and whether a specific patient will actually need a biopsy and/or other tests to confirm diagnosis. … READ MORE…
Filed under: Diagnosis, Risk | Tagged: future, risk, screening, test, urine | 1 Comment »
As we advised readers yesterday, a newly published study by Gregg et al. from the M. D. Anderson Cancer Center has given some clear indications that men diagnosed with lower-risk forms of prostate cancer who are initially managed on active surveillance (AS) can benefit — in terms of time to disease progression — from what is known as the Mediterranean-type diet. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, diet, disease, Mediterranean, progression, risk, surveillance | 4 Comments »
The abstract of a newly published study on the use of the Mediterranean diet (MD) by men on active surveillance (AS) for management of low-risk, localized prostate cancer states that … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, diet, low risk, Mediterranean, surveillance | 4 Comments »
Earlier today, the US Food and Drug Administration (FDA) approved relugolix, (Orgovyx, from Myovant Sciences), the first, oral luteinizing hormone releasing hormone (LHRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: antagonist, GnRH, LHRH, Myovant, Orgovyx, relugolix | 6 Comments »
